Indications and Usage: For determining cardiac output, hepatic function and liver blood flow, and for ophthalmic angiography.

Similar documents
SUMMARY OF PRODUCT CHARACTERISTICS

HYDROCORTISONE OINTMENT USP,


TABLE 1 Principal Radiation Emission Data Radiation Mean % per Disintegration Mean Energy (kev) Gamma

GALLIUM CITRATE Ga 67 INJECTION

Each gram of the ointment contains 0.25 mg Fluocinolone Acetonide in a base containing White Petrolatum.

Click Here to Continue. Click Here to Return to Table of Contents

DRAXIMAGE MDP-25 Kit for the Preparation of Technetium Tc 99m Medronate Injection. For Intravenous Use DIAGNOSTIC FOR SKELETAL IMAGING

DBL NALOXONE HYDROCHLORIDE INJECTION USP

CLINICAL PHARMACOLOGY

AquaMEPHYTON (PHYTONADIONE) Aqueous Colloidal Solution of Vitamin K 1

LEUCOVORIN CALCIUM - leucovorin calciumâ tabletâ Barr Laboratories Inc LEUCOVORIN CALCIUM TABLETS USP Â Rx only

*Sections or subsections omitted from the full prescribing information are not listed.

Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1% (Sterile) Rx only

ROSOBAC-1GM / ROSOBAC-FORT

(angiotensin II) injection for intravenous infusion

Rasburicase 1.5 mg/ml powder and solvent for concentrate for solution for infusion. FASTURTEC

GLUCEPTATE. Technetium Tc 99m Gluceptate Kit DIAGNOSTIC DESCRIPTION

For topical use only. Not for oral, ophthalmic, or intravaginal use.

DESCRIPTION Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. The structural formula is as follows:

VITAMIN K 1 INJECTION Phytonadione Injectable Emulsion, USP Aqueous Dispersion of Vitamin K 1

PHARMACY DOSING AND ORDERING GUIDE

DRAXIMAGE SODIUM IODIDE I 131 CAPSULES, USP DIAGNOSTIC. For Oral Use DESCRIPTION

HIGHLIGHTS OF PRESCRIBING INFORMATION

PACKAGE INSERT USP ANTIBIOTIC

For the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA

SUMMARY OF PRODUCT CHARACTERISTICS

PRESCRIBING INFORMATION. Dextrose Injection USP. (Concentrated Dextrose for Intravenous Administration) 50% (500 mg/ml) Fluid and Nutrient Replenisher

The legally binding text is the original French version

Erythrocyte and Plasma Volume Measurement

NORMOSOL -R MULTIPLE ELECTROLYTES INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid Flexible Plastic Container

CSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1

HIGHLIGHTS OF PRESCRIBING INFORMATION

R: March, E D T P A. Kit for the Preparation of Technetium Tc 99m Pentetate Injection. DIAGNOSTIC - For Intravenous Use

PACKAGE INSERT CALCIUM GLUCONATE INJECTION, USP 10% Electrolyte Replenisher mosmol/ml 680 mosmol/l Ca meq/ml ph

Pharmacy Instructions for Preparation

Viroptic (trifluridine) solution [Monarch Pharmaceuticals, Inc.]

DRAXIMAGE SODIUM IODIDE I 131 SOLUTION USP DIAGNOSTIC. For Oral Use DESCRIPTION

Draft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)

ELSPAR (asparaginase) For injection, intravenous or intramuscular Initial U.S. Approval: 1978

CLINICAL PHARMACOLOGY

The chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

FLUOCINOLONE ACETONIDE-

PRODUCT INFORMATION. BiCNU (Carmustine)

NEW ZEALAND DATA SHEET

PHYSICAL CHARACTERISTICS

DOVONEX (calcipotriene) Cream, 0.005% Rx only FOR TOPICAL DERMATOLOGIC USE ONLY. Not for Ophthalmic, Oral or Intravaginal Use.

Click Here to Continue. Click Here to Return to Table of Contents

CLINICAL PHARMACOLOGY

Artesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

Tranexamic acid, USP is a white crystalline powder. The aqueous solution for injection has a ph of 6.5 to 8.0.

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

CLINICAL PHARMACOLOGY

1 INDICATIONS AND USAGE. 1.1 Limitation of Use FULL PRESCRIBING INFORMATION

NEOSPORIN G.U. Irrigant Sterile (neomycin sulfate polymyxin B sulfate solution for irrigation)

APPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS

PRODUCT INFORMATION. DESCRIPTION Addaven is a concentrated trace element solution for infusion which is clear and colourless to slightly yellow.

6. Production or formation of plasma protein and clotting factors and heparin.

Trifluridine Ophthalmic Solution, 1% Sterile

Konakion MM. Phytomenadione Composition. Properties and effects. Pharmacokinetics

PRESCRIBING INFORMATION ADRENALIN TOPICAL SOLUTION. Epinephrine Chloride Topical Solution, manufacturer standard 30 mg / 30 ml (1 mg/ml)

Artesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

GlucaGen (glucagon [rdna origin] for injection) Initial U.S. Approval: 1998

Chemical Name: 4H-Pyrano[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-, disodium salt.

Step-by-step instructions for intravenous (iv) infusions for patients with:

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 40 g/l is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin.

Cordran Cream and Cordran Ointment Flurandrenolide, USP

SUMMARY OF PRODUCT CHARACTERISTICS

Administer as an intravenous infusion over 35 to 60 minutes (2.1, 2.3) Dilution required prior to administration (2.2)

CEREZYME Genzyme. 70 mg (52 mg) (18 mg)

Sodium Iodide I 131 Solution. Click Here to Continue. Click Here to Return to Table of Contents

GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (em-plis-city)

PRODUCT INFORMATION. Colistin Link. Colistin 150 mg/2 ml (as colistimethate sodium) powder for injection vial

Please see accompanying Full Prescribing Information.

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)

Rx only FOR TOPICAL DERMATOLOGIC USE ONLY, NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE

YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE

Package leaflet: Information for the user. ReoPro 2 mg/ml solution for injection or infusion. abciximab

VIROPTIC Ophthalmic Solution, 1% Sterile (trifluridine ophthalmic solution)

Rat cholesterol ELISA Kit

Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg

3. PHARMACEUTICAL FORM Solution for infusion. A clear, slightly viscous liquid; it is almost colourless, yellow, amber or green.

Calcium Folinate Solution for Injection

ADMINISTRATION GUIDE

AMIODARONE and DESETHYLAMIODARONE IN PLASMA BY UV FAST CODE Z33610

VORAXAZE (glucarpidase) For Injection, for intravenous use Initial U.S. Approval: 2012

RECONSTITUTION, DOSING AND ADMINISTRATION

Powder for reconstitution for use in central venous access devices

3% Sorbitol Urologic Irrigating Solution in UROMATIC Plastic Container

Table 1 Principal Radiation Emission Data * Disintegration. Gamma Ka 1 X-ray

SUMMARY OF PRODUCT CHARACTERISTICS. for. BRIDATEC, kit for radiopharmaceutical preparation

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

3 DOSAGE FORMS AND STRENGTHS

RECENT MAJOR CHANGES INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION

Transcription:

INDOCYANINE GREEN - INDOCYANINE GREEN - indocyanine green injection, powder, lyophilized, for solution Novadaq Technologies Inc. ---------- Indocyanine Green for Injection USP Rx Only Description: Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously. Indocyanine green is a water-soluble, tricarbocyanine dye with peak spectral absorption at 800 nm. The chemical name for Indocyanine Green is 1H-benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3- (4-sulfobutyl)-2H-benz[e]indo-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium, or 2-[7-[1,1-dimethyl-3-(4-sulfobutyl)benz[e]indolin-2-ylidene]-1,3,5- heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-1h-benz[e]indolium hydroxide, inner salt, sodium salt. Indocyanine Green for Injection USP has a ph of approximately 6.5 when reconstituted. Each vial of Indocyanine Green for Injection USP contains 25 mg of indocyanine green as a sterile lyophilized powder. Clinical Pharmacology: Following intravenous injection, Indocyanine Green is rapidly bound to plasma protein, of which albumin is the principle carrier (95%). Indocyanine Green undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. Indocyanine Green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin. These characteristics make Indocyanine Green a helpful index of hepatic function. The plasma fractional disappearance rate at the recommended 0.5 mg/kg dose has been reported to be significantly greater in women than in men, although there was no significant difference in the calculated value for clearance. Indications and Usage: For determining cardiac output, hepatic function and liver blood flow, and for ophthalmic angiography. Contraindications: Indocyanine Green for Injection USP contains sodium iodide and should be used with caution in patients who have a history of allergy to iodides. Warnings: Anaphylactic deaths have been reported following Indocyanine Green for Injection USP administration during cardiac catheterization. https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 1/10

Precautions: General: Indocyanine Green Powder and Solution: Indocyanine Green is unstable in aqueous solution and must be used within 6 hours. However, the dye is stable in plasma and whole blood so that samples obtained in discontinuous sampling techniques may be read hours later. Sterile techniques should be used in handling the dye solution as well as in the performance of the dilution curves. Indocyanine Green powder may cling to the vial or lump together because it is freeze-dried in the vials. Drug Interactions: Heparin preparations containing sodium bisulfite reduce the absorption peak of Indocyanine Green in blood and, therefore, should not be used as an anticoagulant or the collection of samples for analysis. Drug/Laboratory Test interactions: Radioactive iodine uptake studies should not be performed for at least a week following the use of Indocyanine Green. Carcinogenesis, Mutagenesis, Impairment or Fertility: No studies have been performed to evaluate the carcinogenicity, mutagenicity, or impairment of feritility Pregnancy: Teratogenic Effects: Pregnancy Category C: Animal Reproduction studies have not been conducted with Indocyanine Green. It is also not known whether Indocyanine Green can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Indocyanine Green should be given to a pregnant woman only if clearly indicated. Nursing Mothers: lt is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Indocyanine Green is administered to a nursing woman. Pediatric Use: Safety and effectiveness in pediatric patients have been established. Adverse Reactions: Anaphylactic or urticarial reactions have been reported in patients with or without history of allergy to iodides. If such reactions occur, treatment with the appropriate agents (e.g., epinephrine, antihistamines, and corticosteroids) should be administered. Overdosage: There are no data available describing the signs, symptoms, or laboratory findings accompanying overdosage. The LD 50 after I.V. administration ranges between 60 and 80 mg/kg in mice, 50 and 70 mg/kg in rats and 50 and 80 mg/kg in rabbits. Dosage and Administration: Indicator-Dilution Studies: Indocyanine Green permits recording of the indicator-dilution curves for both diagnostic and research https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 2/10

Indocyanine Green permits recording of the indicator-dilution curves for both diagnostic and research purposes independently of fluctuations in oxygen saturation. In the performance of dye dilution curves, a known amount of dye is usually injected as a single bolus as rapidly as possible via a cardiac catheter into selected sites in the vascular system. A recording instrument (oximeter or densitometer) is attached to a needle or catheter for sampling of the dye-blood mixture from a systematic arterial sampling site. Under sterile conditions, the Indocyanine Green for Injection USP powder should be dissolved with Sterile Water for Injection, USP, and the solution used within 6 hours after it is prepared. If a precipitate is present, discard the solution. The amount of solvent to be used can be calculated from the dosage form which follows. It is recommended that the syringe used for injection of the dye be rinsed with this diluent. Saline is used in all other parts of the catheterization procedure. This matter of rinsing the dye syringe with distilled water may not be critical, since it is known that an amount of sodium chloride sufficient to make an isotonic solution may be added to dye that has first been dissolved in distilled water. This procedure has been used for constant-rate injection techniques without precipitation of the dye. The usual doses of Indocyanine Green which have been used for dilution curves are as follows: - Adults-5 mg - Children-2.5 mg - Infants-1.25 mg These doses of the dye are usually injected in a 1-mL volume. An average of five dilution curves is required in the performance of a diagnostic cardiac catheterization. The total dose of dye injected should be kept below 2 mg/kg. Calibrating Dye Curves: To quantitate the dilution curves, standard dilutions of Indocyanine Green in whole blood are made as follows: It is strongly recommended that the same dye that was used for the injections be used in the preparation of these standard dilutions. The most concentrated dye solution is made by accurately diluting 1 ml of the 5-mg/mL dye with 7 ml of distilled water. This concentration is then successively halved by diluting 4 ml of the previous concentration with 4 ml of distilled water. (If a 2.5 mg/ml concentration was used for the dilution curves, 1 ml of the 2.5 mg/ml dye is added to 3 ml of distilled water lo make the most concentrated "standard' solution. This concentration is then successively halved by diluting 2. ml of the previous concentration with 2 ml of distilled water.) Then 0.2-mL portions (accurately measured from a calibrated syringe) of these dye solutions are added to 5-mL aliquots of the subject's blood, giving final concentrations of the dye in blood beginning with 24 mg/liter, approximately (actual concentration depends on the exact volume of dye added). This concentration is, of course, successively halved in the succeeding aliquots of the subject's blood. These aliquots of blood containing known amounts of dye, as well as a blank sample to which 0.2 ml of saline containing no dye has been added, are then passed through the detecting instrument and a calibration curve is constructed from the deflections recorded. Hepatic Function Studies: Due to its absorption spectrum, changing concentrations of Indocyanine Green in the blood can be monitored by ear densitometry or by obtaining blood specimens at timed intervals. The technique for both methods is as follows. The patient should be studied in a fasting, basal state. The patient should be weighed and the dosage calculated on the basis of 0.5 mg/kg of body weight. Under sterile conditions, the Indocyanine Green for Injection USP powder should be dissolved with Sterile Water for Injection, USP. Exactly 5 ml of Sterile Water for Injection, USP, should be added to the 25-mg vial, giving 5 mg of dye per ml of solution. Inject the correct amount of dye into the lumen of an arm vein as rapidly as possible, without allowing the dye to escape outside the vein, (If the photometric method is used, prior to injecting Indocyanine Green, withdraw 6 ml of venous blood from the patient's arm for serum blank and standard curve construction, and through the same needle, inject the correct amount of dye.) https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 3/10

construction, and through the same needle, inject the correct amount of dye.) Ear Densitometry: Ear oximetry has also been used and makes it possible to monitor the appearance and disappearance of Indocyanine Green without the necessity of withdrawal and spectrophotometric analysis of blood samples for calibration. An ear densitometer which has a compensatory photoelectric cell to correct for changes in blood volume and hematocrit, and a detection photocell which registers levels has been described. This device permits simultaneous measurement of cardiac output, blood volume and hepatic clearance of Indocyanine Green' and was found to provide a reliable index of plasma removal kinetics after single injections or continuous infusions of Indocyanine Green. This technique was employed in newborn infants, healthy adults and in children and adults with liver disease. The normal subject has a removal rate of 18-24% per minute. Due to the absence of extra-hepatic removal, Indocyanine Green was found to be ideally suited for serial study of severe chronic liver disease and to provide a stable measurement of hepatic blood flow. In larger doses, Indocyanine Green has proven to be particularly valuable in detecting drug-induced alterations of hepatic function and in the detection of mild liver injury. Using the ear densitometer, a dosage of 0.5 mg/kg in normal subjects gives the following clearance pattern. *Dichromatic earpiece densitometer supplied by The Waters Company, Rochester, Minnesota. Photometric Method Determination Using Percentage Retention of Dye: A typical curve obtained by plotting dye concentration versus optical density is shown opposite. Percent retention can be read from this plot. If more accurate results are desired, a curve using the patient's blood and the vial of Indocyanine https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 4/10

If more accurate results are desired, a curve using the patient's blood and the vial of Indocyanine Green being used in the determination can be constructed as follows: 1. Take 6 ml of non-dye-containing venous blood from the patients arm. Place in a test tube and allow the blood to clot. The serum is separated by centrifugation. 2. Pipette 1 ml. of the serum into a microcuvette. 3. Add 1 lambda (λ) of the 5-mg/mL aqueous Indocyanine Green solution to the serum, giving a dilution of 5 mg/liter, the standard for 50% retention. (The addition of 2 lambda (λ) of the 5- mg/ml Indocyanine Green solution would give 100% retention; however, this concentration cannot be read on the spectrophotometer.) 4. The optical density of this solution is read at 805 nm, using normal serum as the blank. 5. Plot the 50% figure obtained in Step 4, and draw a line connecting this point with the zero coordinates. Percentage Retention: A single 20-minute sample (withdrawn from a vein in the opposite arm that injected) is allowed to clot, centrifuged, and its optical density is determined at 805 nm using the patients normal serum as the blank. Dye concentration is read from the curve above. A single 20-minute sample of serum in healthy subjects should contain no more than 4% of the initial concentration of the dye. The use of percentage retention is less accurate than percentage disappearance rate but provides reproducible results. Hemolysis does not interfere with a reading. Determination Using Disappearance Rate of Dye: To calculate the percentage disappearance rate, obtain samples at 5, 10, 15 and 20 minutes after injecting the dye. Prepare the sample as in the previous section and measure the opticai densities at 805 nm, using the patient's normal serum as the blank. The Indocyanine Green concentration in each timed specimen can be determined by using the concentration curve illustrated. Plot values- on semilogarithmic paper. Specimens containing Indocyanine Green should be read at the same temperature since Its optical density is influenced by temperature variations. Normal Values: Percentage disappearance rate in healthy subjects is 18-24% per minute. Normal biological half-time is 2.5-3.0 minutes. Ophthalmic Angiography Studies: The excitation and emission spectra (Figure 1) and the absorption spectra (Figure 2) of Indocyanine Green make it useful in ophthalmic angiography. The peak. absorption and emission of Indocyanine Green lie in a region (800-850 nm) where transmission of energy by the pigment epithelium is more efficient than in the region of visible light energy. Indocyanine Green also has the property of being nearly 98% bound to blood protein, and therefore, excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature. It is, therefore, useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus- camera. https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 5/10

Dosages up to 40 mg Indocyanine Green dye in 2 ml of Sterile Water for Injection, USP, have been found to give optimal angiograms, depending on the imaging equipment and technique used. The antecubital vein injected Indocyanine Green dye bolus should immediately be followed by a 5-mL bolus of normal saline. Clinically, angiograms of uniformly good quality can be assured only after taking care to optimize the contributions of all possible factors, such as patient cooperation and dye injection. The foregoing injection regimen is designed to provide delivery of a spatially limited dye bolus of optimal concentration to the choroidal vasculature following intravenous injection. How Supplied: Indocyanine Green for Injection USP. is supplied in a kit, containing six 25-mg Indocyanine Green for Injection USP vials and six 10-mL sterile Water for Injection vials: NDC 75874-424-01:Indocyanine Green for Injection USP 25-mg filled in 30 ml vial. NDC 63323-185-10 Sterile Water for Injection 10-mL fill in 10-mL vial. Storage: Store at 20 to 25 C [68 to 77 F). [See USP Controlled Room Temperature.] Rx only Manufactured by: Patheon Italia S.p.A. Viale G.B. Stucchi 110 20900 Monza (MB) ITALY and Pulsion Medical Systems SE Hans-Riedl-Straβe 17 D-85622 Feldkirchen, Germany Manufactured for Novadaq Technologies Inc. Richmond, BC V6V 2A2 Canada Distributed by: LifeCell Corporation Brachburg, NJ 08876 Sterile Water for Injection USP is Manufactured by: Abraxis Pharmaceutical Products Schaumburg, IL 60173 Oct 2011/Rev.00 https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 6/10

Oct 2011/Rev.00 Cod. 251316 Principal Display Panel Vial Label NDC 75874-424-01 25 mg/vial Indocyanine Green for Injection USP After reconstitution, use within 6 hours R only Sterile x Manufactured for Novadaq by: Distributed by: Patheon Italia, S.p.A. and PULSION Medical Systems LifeCell Corporation INDOCYANINE GREEN indocyanine green kit Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:75874-820 Packaging # Item Code Package Description Multilevel Packaging 1 NDC:75874-820-02 6 PACKAGE (6 PACKAGE) in 1 CARTON contains a PACKAGE 1 1 KIT (1 KIT) in 1 PACKAGE This package is contained within the CARTON (75874-820-02) https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 7/10

QUANTITY OF PARTS Part # Package Quantity Total Product Quantity Part 1 1 VIAL, GLASS 1 Part 2 1 VIAL, PLASTIC 10 ml Part 1 of 2 INDOCYANINE GREEN indocyanine green injection, powder, lyophilized, for solution Product Information Item Code (Source) NDC:75874-424 Route of Administration INTRAVENOUS DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Indocyanine green (Indocyanine green) Indocyanine green 25 mg Inactive Ingredients Ingredient Name sodium iodide Strength Product Characteristics Color Score Shape Flavor Contains Size Imprint Code Packaging # Item Code Package Description Multilevel Packaging 1 75874-424-01 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (1 VIAL) in 1 VIAL, GLASS None Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040811 12/01/2011 https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 8/10

Part 2 of 2 STERILE WATER water injection Product Information Item Code (Source) NDC:63323-185 Route of Administration INTRAVENOUS DEA Schedule Inactive Ingredients Ingredient Name water Strength Product Characteristics Color Score Shape Flavor Contains Size Imprint Code Packaging # Item Code Package Description Multilevel Packaging 1 63323-185-10 10 ml in 1 VIAL, PLASTIC None Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040811 07/20/1981 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040811 07/20/1981 INDOCYANINE GREEN indocyanine green injection, powder, lyophilized, for solution https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 9/10

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:75874-424 Route of Administration INTRAVENOUS DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Indocyanine green (Indocyanine green) Indocyanine green 25 mg Inactive Ingredients Ingredient Name sodium iodide Strength Product Characteristics Color Score Shape Flavor Contains Size Imprint Code Packaging # Item Code Package Description Multilevel Packaging 1 NDC:75874-424-01 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (1 VIAL) in 1 VIAL, GLASS None Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040811 12/01/2011 Labeler - Novadaq Technologies Inc. (203343858) Revised: 11/2011 Novadaq Technologies Inc. https://rm2.scinet.fda.gov/druglabel/rs/spl/by-id/57622/57622.html 10/10